Latest Insider Transactions at Akoya Biosciences, Inc. (AKYA)
This section provides a real-time view of insider transactions for Akoya Biosciences, Inc. (AKYA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Akoya Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Akoya Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2024
|
Brian Mc Kelligon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+26.71%
|
-
|
|
Dec 19
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-4.69%
|
$30,000
$4.48 P/Share
|
|
Dec 19
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.48%
|
$0
$0.3 P/Share
|
|
Dec 12
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-4.69%
|
$30,000
$4.25 P/Share
|
|
Dec 12
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.48%
|
$0
$0.3 P/Share
|
|
Nov 20
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-4.69%
|
$30,000
$4.39 P/Share
|
|
Nov 20
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.48%
|
$0
$0.3 P/Share
|
|
Nov 06
2023
|
Jennifer Kamocsay Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+30.77%
|
-
|
|
Nov 06
2023
|
Frederic Pla Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+29.83%
|
-
|
|
Sep 07
2023
|
Frederic Pla Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
20,000
+37.96%
|
$80,000
$4.6 P/Share
|
|
Jun 12
2023
|
Thomas A. Raffin Director |
BUY
Open market or private purchase
|
Indirect |
2,020,000
+9.4%
|
$10,100,000
$5.0 P/Share
|
|
Jun 12
2023
|
Robert G Shepler Director |
BUY
Open market or private purchase
|
Indirect |
120,000
+24.51%
|
$600,000
$5.0 P/Share
|
|
Jun 12
2023
|
Matthew Winkler Director |
BUY
Open market or private purchase
|
Direct |
203,388
+17.12%
|
$1,016,940
$5.0 P/Share
|
|
Jun 12
2023
|
Scott Mendel Director |
BUY
Open market or private purchase
|
Direct |
20,000
+41.24%
|
$100,000
$5.0 P/Share
|
|
Jun 12
2023
|
Goldman Myla Lai Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$100,000
$5.0 P/Share
|
|
Jun 12
2023
|
John Frederick Ek CFO |
BUY
Open market or private purchase
|
Indirect |
20,000
+50.0%
|
$100,000
$5.0 P/Share
|
|
Jun 06
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-3.17%
|
$25,000
$5.71 P/Share
|
|
Jun 06
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.08%
|
$0
$0.3 P/Share
|
|
Mar 23
2023
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,945
-1.09%
|
$13,615
$7.69 P/Share
|
|
Mar 23
2023
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,437
-4.65%
|
$52,059
$7.69 P/Share
|
|
Mar 23
2023
|
Frederic Pla Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,945
-4.58%
|
$13,615
$7.69 P/Share
|
|
Mar 20
2023
|
Jennifer Kamocsay Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+50.0%
|
-
|
|
Mar 20
2023
|
John Frederick Ek CFO |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+50.0%
|
-
|
|
Mar 14
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.52%
|
$45,000
$9.53 P/Share
|
|
Mar 14
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.94%
|
$0
$0.3 P/Share
|
|
Feb 23
2023
|
Niro Ph.D Ramachandran Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+11.16%
|
-
|
|
Feb 23
2023
|
Frederic Pla Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+32.0%
|
-
|
|
Feb 23
2023
|
Ehab El Gabry Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+50.0%
|
-
|
|
Feb 23
2023
|
Marilee Moy CHIEF PEOPLE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Feb 23
2023
|
Brian Mc Kelligon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+33.33%
|
-
|
|
Feb 15
2023
|
Niro Ph.D Ramachandran Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+17.83%
|
$0
$0.91 P/Share
|
|
Dec 22
2022
|
Joseph Driscoll Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+48.78%
|
$0
$0.44 P/Share
|
|
Dec 14
2022
|
Joseph Driscoll Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
24,613
-49.19%
|
$295,356
$12.57 P/Share
|
|
Dec 14
2022
|
Joseph Driscoll Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,613
+32.9%
|
$0
$0.44 P/Share
|
|
Dec 13
2022
|
Thomas P Schnettler Director |
SELL
Open market or private sale
|
Indirect |
71,050
-2.53%
|
$923,650
$13.03 P/Share
|
|
Dec 06
2022
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-5.88%
|
$60,000
$12.08 P/Share
|
|
Dec 06
2022
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.56%
|
$0
$0.3 P/Share
|
|
Dec 02
2022
|
Garry Ph.D. Nolan Director |
SELL
Open market or private sale
|
Direct |
1,100
-0.19%
|
$14,300
$13.25 P/Share
|
|
Dec 01
2022
|
Garry Ph.D. Nolan Director |
SELL
Open market or private sale
|
Direct |
5,000
-0.84%
|
$65,000
$13.36 P/Share
|
|
Nov 16
2022
|
Garry Ph.D. Nolan Director |
SELL
Open market or private sale
|
Direct |
300
-0.05%
|
$3,900
$13.25 P/Share
|
|
Nov 14
2022
|
Garry Ph.D. Nolan Director |
SELL
Open market or private sale
|
Direct |
600
-0.1%
|
$7,800
$13.28 P/Share
|
|
Nov 11
2022
|
Garry Ph.D. Nolan Director |
SELL
Open market or private sale
|
Direct |
20,000
-3.23%
|
$260,000
$13.29 P/Share
|
|
Nov 10
2022
|
Garry Ph.D. Nolan Director |
SELL
Open market or private sale
|
Direct |
3,810
-0.61%
|
$49,530
$13.31 P/Share
|
|
Sep 14
2022
|
Garry Ph.D. Nolan Director |
SELL
Open market or private sale
|
Direct |
8,305
-1.32%
|
$107,965
$13.26 P/Share
|
|
Sep 12
2022
|
Garry Ph.D. Nolan Director |
SELL
Open market or private sale
|
Direct |
1,800
-0.28%
|
$23,400
$13.3 P/Share
|
|
Sep 09
2022
|
Garry Ph.D. Nolan Director |
SELL
Open market or private sale
|
Direct |
22,191
-3.39%
|
$288,483
$13.31 P/Share
|
|
Sep 07
2022
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-5.88%
|
$60,000
$12.83 P/Share
|
|
Sep 07
2022
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.56%
|
$0
$0.3 P/Share
|
|
Jun 15
2022
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-5.88%
|
$50,000
$10.25 P/Share
|
|
Jun 15
2022
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.56%
|
$0
$0.3 P/Share
|